X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This paper illustrates that the COVID-EDV vaccine is a fundamental change in thinking on how to produce an effective and inexpensive vaccine and has broad-reaching ramifications for vaccinology.
Lead Product(s): COVID-EDV
Therapeutic Area: Infections and Infectious Diseases Product Name: COVID-EDV
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
Details:
Under the deal, EnGeneIC will grant ImmunityBio an exclusive, worldwide licence to develop, manufacture and commercialize EDV™ in combination with its anti-cancer drugs and COVID-19 vaccine.
Lead Product(s): EnGeneIC Dream Vector,Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: EDV
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ImmunityBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 30, 2021
Details:
Abstract demonstrates promising early results from PHASE I/IIA study in patients with recurrent, metastatic pancreatic cancer.
Lead Product(s): E-EDV-D682,EDV-GC
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
